Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that
 angiogenesis is very important for these tumors to progress. Preclinical data is suggesting
 this. This is why we we prospectively want to treat these patients with avastin (and
 doxorubicin). However, local control is of major concern. Therefore, patients are initially
 treated with hyperfractionated radiotherapy and undergo surgery. Then they can enter this
 study.
Patients with Anaplastic Thyroid Cancer have a poor prognosis. We will treat the patients
 initially with our standard radiochemotherapy, which consists of doxorubicin 20mg fixed
 dose/week and hyperfractionated radiotherapy 1,6 Gy twice daily up to 46 Gy in total. The
 first week during radiotherapy, they will also receive Avastin 15mg/kg. 1-2 weeks after
 radiotherapy patients will undergo surgery of their primary tumor. After this "standard"
 therapy patients can be included in this study. Treatment is 20 mg fixed dose doxorubicin q1w
 and avastin 15mg/kg q3w. Treatment will continue maximum 6 months or until progress or until
 intolerable side effects occur.
Inclusion Criteria:

 -  cytologically or histologically verified anaplastic thyroid cancer

 -  completed standard therapy

 -  operated with R0 or R1 surgery

 -  Performance Status 0-2 (if pulmonary mets PS 0-1)

 -  normal wound healing

 -  neutrophils > 1,5 million/ml

 -  platelets > 100 million/ml

 -  bilirubin < 2 ULN

 -  creatinin < 150mikromol/L

 Exclusion Criteria:

 -  PS 3-4 (if pulmonary mets 2-4)

 -  R2 resection of primary tumor